Every year, without fail, the Endpoints 11 proves to be the most challenging project I face — and definitely remains the most fun.
In an industry where ambition and zeal are trademarks of the most exciting biotechs, how do you narrow the list down to 11 of the most worthy…
Click here to view original post
